1. Ruiz-Fernández de Córdoba, Borja, Martínez-Monge, Rafael, Lecanda, Fernando. . ENPP1 Immunobiology as a Therapeutic Target. In Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 2184-2193. doi:10.1158/1078-0432.CCR-22-1681. https://pubmed.ncbi.nlm.nih.gov/36719675/
2. Iwamoto, Takayuki, Kajiwara, Yukiko, Zhu, Yidan, Iha, Shigemichi. 2020. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. In Chinese clinical oncology, 9, 27. doi:10.21037/cco.2020.01.06. https://pubmed.ncbi.nlm.nih.gov/32192349/
3. Hunter, Francis W, Barker, Hilary R, Lipert, Barbara, Sotiriou, Christos, Jamieson, Stephen M F. 2019. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. In British journal of cancer, 122, 603-612. doi:10.1038/s41416-019-0635-y. https://pubmed.ncbi.nlm.nih.gov/31839676/
4. Buettner, Ralf, Nguyen, Le Xuan Truong, Morales, Corey, Marcucci, Guido, Rosen, Steven T. 2021. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. In Journal of hematology & oncology, 14, 70. doi:10.1186/s13045-021-01076-4. https://pubmed.ncbi.nlm.nih.gov/33902674/
智鼠故事 
